Histone deacetylase (HDAC) inhibitors (PXDLOL) for the treatment of cancer alone or in combination with chemotherapeutic agent

Details for Australian Patent Application No. 2006313517 (hide)

Owner TopoTarget UK Limited Curagen Corporation

Inventors Petersen, Kamille Dumong; Ritchie, James; Plumb, Jane; Edwards, Nicholas; Lichtenstein, Henri

Agent FB Rice

Pub. Number AU-A-2006313517

PCT Pub. Number WO2007/054719

Priority 60/735,701 10.11.05 US

Filing date 10 November 2006

Wipo publication date 18 May 2007

International Classifications

A61K 31/10 (2006.01)

A61K 31/196 (2006.01)

A61K 31/475 (2006.01) - having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine

A61K 31/573 (2006.01)

A61K 31/65 (2006.01) - Tetracyclines

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

15 May 2008 PCT application entered the National Phase

  PCT publication WO2007/054719 Priority application(s): WO2007/054719

5 June 2008 Corrigenda

  PCT applications that have entered the National Phase - Name Index Under the name TopoTarget UK Limited and Curagen Corporation, Application No. 2006313517, Under (71), correct the name to TopoTarget UK Limited and CuraGen Corporation.

31 March 2011 Assignment before Grant

  CuraGen Corporation; TopoTarget UK Limited The application has been assigned to TopoTarget UK Limited

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006313518-Reprogramming and genetic modification of cells

2006313509-Device for strapping packages with strap material